Vimarsana
Biggest News Aggregation in the World

Daniel Glaze News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Daniel Glaze. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Daniel Glaze Today - Breaking & Trending Today

Staffing State of Emergency for Calif. Police Department Extended - Vimarsana News

Staffing State of Emergency for Calif. Police Department Extended

Although the Vallejo Police Department is facing critical staffing levels, the situation is improving as the agency goes to 12-hour shifts and works through the phases of the ...

POW Father Emil Kapaun honored, laid to rest in funeral Mass - Vimarsana News

POW Father Emil Kapaun honored, laid to rest in funeral Mass

“We are here today to provide for him what was not provided for him 70 years ago, a Mass of Christian burial,” said Bishop Carl A. Kemme during the funeral Mass on Wednesday, Sept. 29, in Park City, Kansas. “And, though we are all praying for his intercession, we must nevertheless pray for his repose as we do for all the dead. This is our Christian duty as we bring him to his new place of rest.” / Beloit St John's Media Wichita, Kan., Sep 30, 2021 / 11:12 am (CNA). On Wednesday, the Diocese of Wichita held a funeral Mass and procession honoring Servant of God Em...

Harmony Biosciences Enrolls First Patient In Phase 2 Trial Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willi Syndrome - Vimarsana News

Harmony Biosciences Enrolls First Patient In Phase 2 Trial Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willi Syndrome

Share this article Share this article PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 15, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the first patient has been enrolled in a Phase 2 trial evaluating the safety and efficacy of pitolisant for the treatment of excessive daytime sleepiness (EDS) and other key symptoms in patients with Prader-Willi Syndrome (PWS). "We view pit...